Ingredion Inc Dossier - Source-backed chat

Ingredion Inc

INGRNYSE

SectorConsumer Staples

IndustryPackaged Foods

Beta (adjusted)0.75

Intrinsic Value $102.24median of 6 methods · middle span $97-$116based on filings through 30 Jun 2026

Market Price $94.91Price as of 1 Oct 2026

Near fair valueIntrinsic value is 8% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $6B

Enterprise Value $6.8B

Shares Outstanding 63.5M diluted

Moat Rating Wide

Next Earnings Date3 Nov 2026

Last ex-dividend1 Jul 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ingredion Incorporated (NYSE: INGR) presents a compelling investment opportunity as a leading global provider of value-added ingredient solutions. Despite recent operational setbacks at its Argo facility that pressured Q1 2026 earnings, the company's underlying business model remains highly resilient, supported by strong cash generation and a robust balance sheet. The transformational $5.0 billion proposed acquisition of Tate & Lyle, announced in June 2026, is highly complementary and is expected to expand Ingredion's specialty ingredients platform, diversify its global footprint, and generate $130 million in annual cost synergies by 2030. Trading at an attractive valuation of under 10x trailing earnings, the risk-reward profile is highly favorable for long-term investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$108.00

Mean target$121.50

High · most bullish analyst$150.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects prolonged integration challenges and delayed synergy realization from the Tate & Lyle acquisition, keeping leverage elevated above 3.0x for more than two years post-close. Continued operational disruptions at major facilities, persistent input cost inflation (energy and logistics), and adverse tariff policies could further compress margins. Additionally, weaker consumer spending in key North American and European markets could lead to softer volumes in food and industrial ingredients.

Base CaseCentral scenario

The base case assumes successful integration of the Tate & Lyle acquisition by the second half of 2027, with the combined entity achieving projected cost synergies and expanding its high-margin specialty ingredients platform. Operational issues at the Argo facility are resolved sequentially, allowing cash from operations to normalize within the guided range of $725 million to $825 million for full-year 2026. Valuation multiples are expected to expand as the company reduces leverage back toward its 2.5x target within 18 months of transaction close.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transformational acquisition of Tate & Lyle expands geographic reach and specialty portfolio, creating a combined entity with nearly $10 billion in revenue.
Strong cash flow generation with guided 2026 cash from operations of $725 million to $825 million, supporting a reliable ~3.2% dividend yield.
Strong growth in the high-margin specialty ingredients platform, with the Texture & Healthful Solutions segment delivering its eighth consecutive quarter of broad-based net sales volume growth in Q1 2026, driven by robust customer demand for clean label ingredients.
Excellent progress in ESG and sustainable sourcing, reaching over 96% sustainably sourced Tier 1 priority crops in 2025.

Key Investment Risks

Elevated leverage post-acquisition of Tate & Lyle, with S&P Global Ratings expecting the company to prioritize reducing its adjusted debt to EBITDA close to 2.5x.
Operational and execution risks, as highlighted by the $40 million negative impact from the Argo facility challenges in Q1 2026.
Exposure to commodity price volatility and foreign exchange translational headwinds, particularly the Mexican peso.
Integration complexities associated with a large-scale, cross-border transaction.

Thesis Invalidation Triggers

Failure to close the Tate & Lyle transaction or significant delays extending past the second half of 2027.
Sustained leverage above 3.0x debt to EBITDA two years after the transaction close, leading to a potential credit rating downgrade from S&P or Fitch.
Further severe operational failures at major manufacturing facilities like Argo or Cedar Rapids.
A material decline in organic volumes within the core Texture & Healthful Solutions segment.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.